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Objectives: The present study was undertaken to assess and compare the immunohistochemical expression of 
Bcl-2 in selected benign and malignant salivary gland tumors.
Study Design: A total of 50 cases of buffered formalin-fixed, paraffin embedded tissues of previously diagnosed 
cases of benign and malignant salivary gland tumors from the archives of Department of Oral and Maxillofacial 
Pathology and Microbiology, SDM College of Dental Sciences and Hospital, Dharwad, India, were taken for the 
study. The immunohistochemical staining procedure was performed using monoclonal anti Bcl-2 antibody, as 
directed by the manufacturer.
Results: Thirty six cases (72%) out of 50 cases showed a positive expression for Bcl-2. Benign salivary gland 
tumors showed a positive expression in 8 out of 14 cases (~57%) and malignant salivary gland tumors in 28 out 
of 36 cases (~78%). The staining was intense in the normal lymph node, which is used as a positive control. Bcl-2 
expression was seen in both benign and in malignant salivary gland tumors taken for the study except in “canal-
icular adenoma”.
Conclusion: The immunohistochemical expression of Bcl-2 was greater and more intense in malignant salivary 
gland neoplasms, suggesting a high survival rate of tumor cells in malignant neoplasms.
Key words: Bcl-2, salivary gland neoplasms, apoptosis, pleomorphic adenoma, adenoid cystic carcinoma, mu-
coepidermoid carcinoma.
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Introduction  
Salivary gland neoplasms are relatively uncommon and 
represent < 2% of all tumors in humans, occurring both 
in major and minor glands. They possess a wide variety 
of histologic appearances and biologic behavior (1). 
Apoptosis is a distinct process of cell death that is re-
sponsible for deletion of aged, injured and altered cells 
in normal and in certain specific pathologies like neo-
plasia (2,3). 
Bcl-2 is the first gene shown to be involved in apoptosis 
and was regarded as a proto-oncogene that suppresses 
the cell death rather than stimulating cell proliferation 
(4,5). The human Bcl-2 protein is an intracellular, inte-
gral membrane protein with a molecular weight of about 
26 kD. 
Bcl-2 expression has been studied in oral epithelial 
dysplasia, oral submucous fibrosis and oral squamous 
cell carcinoma and its expression showed increasing 
with the severity of dysplasia and decreased expres-
sion in differentiation of oral carcinoma (6,7). Bcl-2 
expression was shown to be downregulated in the ma-
lignant transformation of ameloblastoma (8). Studies of 
Bcl-2 expression in salivary gland tumors are limited 
and largely confined to few tumors and also in small 
number of cases. 
Materials and Methods
A total of 50 cases of buffered formalin-fixed, paraffin 
embedded tissues of previously diagnosed cases of be-
nign and malignant salivary gland tumors were selected 
from the archives of Department of Oral and Maxillofa-
cial Pathology and Microbiology, SDM College of Den-
tal Sciences and Hospital, Dharwad, India, to assess the 
immunohistochemical expression of Bcl-2. 
The benign tumors such as pleomorphic adenoma (9 
cases), myoepithelioma (3 cases), and canalicular ad-
enoma (2 cases) and malignant tumors such as adenoid 
cystic carcinoma (majority of them had a mixture of 
cribriform and tubular patterns) (ACC) (21 cases), mu-
coepidermoid carcinoma (MEC) (11 cases), and adeno-
carcinoma not otherwise specified (NOS) (4 cases) were 
taken for the study.
Immunohistochemical staining procedure: Serial sec-
tions of 4μm thickness were taken on silanised slides 
(S 4651, SIGMA DIAGNOSTICS, USA) meant for im-
munohistochemistry. The sections were deparaffinised 
in xylene for 5 minutes, hydrated through graded al-
cohols for 3 minutes each and washed with Tris buff-
er saline (TBS). Endogenous peroxidase activity was 
blocked with 3% H2O2 in methanol for 10 minutes. The 
antigen retrieval was performed by heating the slides 
in a pressure cooker containing 10 mM citrate buffer 
(pH 6.0) solution for 5 minutes. The sections were in-
cubated with the primary antibody, anti Bcl-2 oncopro-
tein (Monoclonal mouse anti-human, clone 124, DAKO, 
CA, USA) for 3 to 4 hours at 30°C in a humidifying 
chamber. The subsequent procedures were done accord-
ing to manufacturer s´ protocol. The standard streptavi-
din - biotin - peroxidase complex method was done to 
bind primary antibody with the use of a LSAB + sys-
tem universal kit (K0679). The reaction products were 
visualized using 0.3% diaminobenzidine solution. The 
specificity of immunohistochemical staining was noted 
by replacing the primary antibody with TBS (negative 
control). 
Finally, the slides were counterstained with Mayer’s 
haematoxylin and mounted using a non-aqueous mount-
ing medium.
Evaluation: The sections were evaluated for the staining 
and the intensity of Bcl-2 expression. Observations were 
made on the basis of intensity of cytoplasmic staining 
which was either invariably finely granular or rarely ho-
mogenous in the majority of the tumor cells. The normal 
lymph node was used as positive control, which showed 
intense staining in the mantle zone. This was compared 
with positive tumor cases for grading purposes. The in-
tensity was graded in all the cases with 0 representing 
no staining, 1, 2 and 3 to represent mild, moderate and 
intense staining respectively. Though judging intensity 
is regarded as subjective, care was taken to reduce the 
subjectivity by 3 independent observations (two other 
observers by senior faculty members in the department) 
and by intra lesional comparison with lymphocytes 
along with positive control, which were intensely posi-
tive for Bcl-2. 
The results obtained were taken for statistical analysis 
by using ‘Chi-Square test’ and ‘Z proportionality test’. 
Results
The Bcl-2 showed a positive immunostaining in 36 cas-
es (72%) out of 50, of which the benign tumors showed 
positive expression in 8/14 (~57%) and malignant tu-
mors in 28/36 (~78%) cases (Table 1). 
The expression and the intensity of staining in indi-
vidual tumors are summarized in table 2. Majority of 
adenoid cystic carcinomas were consistently positive 
for Bcl-2. Different histologic types of adenoid cystic 
carcinomas (cribriform and tubular patterns) showed a 
positive expression for Bcl-2 (Fig. 1), but varied in the 
intensity of staining. 
Among the positive cases of mucoepidermoid carcino-
ma, most of the mucous cells were negative except for 
one case, which showed intense homogenous staining. 
The epidermoid and intermediate cells were usually 
positive (Fig. 2). 
No statistical significance was observed with regard to 
intensity of Bcl-2 expression in benign and malignant 
tumors (χ2 = 3.7217).
Since the sample of cases in each of the tumor types 
(except for adenoid cystic carcinoma) were limited and 
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Serial No Lesion No of Cases Positive cases % of Bcl-2 positivity 
1 Pleomorphic Adenoma 09 05 55 % 
2 Myoepithelioma 03 03 100% 
3 Canalicular Adenoma 02 00 0% 
4 Adenoid cystic carcinoma 21 21 100% 
5 Mucoepidermoid carcinoma 11 05 45% 
6 Adenocarcinoma NOS 04 02 50% 






Mild Moderate Intense 
1 Pleomorphic Adenoma 05 5 0 0 
2 Myoepithelioma 03 2 0 1 
3 Adenoid cystic Carcinoma 21 7 6 8 
4 Mucoepidermoid Carcinoma 05 3 1 1 
5 Adenocarcinoma 02 1 0 1 
Total cases          36 18 7       11 
Table 1. Bcl-2 expression in different Benign and Malignant Salivary Gland Tumors.
Table 2. Intensity of Bcl-2 expression in various Benign and Malignant Salivary gland Tumors.
Fig. 1. Photomicrograph showing intense Bcl-2 expression in cri-
briform pattern of ACC (250X).
Fig. 2. Photomicrograph showing intense Bcl-2 expression in epider-
moid cells in MEC (250X).
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varied greatly in the staining intensity of the positive 
cases, no meaningful statistical analysis was rendered. 
There’s not much difference in the intensity of expres-
sion of Bcl-2 in all 21 cases of adenoid cystic carcino-
ma. 
Discussion 
Bcl-2 proto-oncogene, endowing B cells with a selec-
tive survival advantage that promotes their neoplastic 
expansion. The concept that defective programmed cell 
death contributes to malignancy was established by 
studies of Bcl-2, representing a major step forward in 
current understanding of tumorigenesis. Experimental 
therapies targeting Bcl-2 family proteins are currently 
in clinical testing have increased hopes that a new class 
of anticancer drugs may be near (9).
Bcl-2 expression is seen in many oral lesions like epi-
thelial dysplasia and carcinoma, benign and malig-
nant ameloblastomas, dentigerous and odontogenic 
keratocysts and also in glandular odontogenic cysts 
(6,7,10,11).
Expression of Bcl-2 is highly variable in epithelial ma-
lignancies. Bcl-2 expression is linked to cell type and 
degree of differentiation. Other factors such as viral 
infection may also contribute to high levels of Bcl-2 in 
epithelial malignancies (5). 
Bcl-2 has been studied in benign salivary tumors such 
as pleomorphic adenoma, myoepithelioma, Warthin’s 
tumor and oncocytoma and in malignant salivary gland 
tumors (12,13).
Very recent study on Bcl-2 oncoprotein in Warthin’s 
tumor suggested a protective role of tumor cells from 
apoptosis to maintain their survival but not to increase 
their malignant potentiality. Elevated Bcl-2 expression 
was related to the possible protection against apopto-
sis. Ninety percent of cases (18 out of 20 cases) showed 
positive expression and both layers of the neoplastic 
epithelium (basal and luminal cells) showed positive 
immunoreactivity, with cytoplasmic localization, sur-
rounded by a negatively stained stroma (14).
The increased expression of Bcl-2 in epidermoid cells 
of MEC can be correlated with increased survival rate 
of these cells and tumors with predominance of these 
cells. A recent report of Bcl-2 expression in MEC by 
Yin et al. (15) concluded that Bcl-2 is one of the poten-
tially useful markers for survival in patients with MEC 
in minor salivary glands.
The lack of Bcl-2 expression in these cells may be 
linked to the degree of differentiation. Terminal differ-
entiated cells like the mucous cells, normal acinar cells, 
salivary gland duct cells also do not express Bcl-2, but 
basal cells of the normal oral epithelium express Bcl-2. 
The mucous and intermediate cells were positive in one 
case.
The intense localization of Bcl-2 expression was found 
in outer cells of tubular pattern, peripheral cells in solid 
pattern and the luminal cells in cribriform pattern. 
In the present study, all the 21 cases (100%) of adenoid 
cystic carcinoma showed positivity. This was similar 
to the earlier findings (12,16). However, the expression 
of Bcl-2 in ACC, in other studies was 30% and 46.2% 
(17,18).
The tumor ductal and myoepithelial cells in the various 
patterns of ACC were positive for Bcl-2. The expression 
of Bcl-2 in these cells can be linked to the lesser degree 
of differentiation compared to normal acinar cells and 
ductal cells of salivary glands. The Bcl-2 positive cells 
are involved in different pattern formation of ACC (Fig. 
1).
Among the four cases of adenocarcinoma two were 
positive for Bcl-2 expression. One case showed focal in-
tense positivity and the other was mildly positive. Our 
findings compares favorably with the only other study 
attributes loss of expression due to differentiation of ba-
saloid cells (19). 
All three cases of myoepithelioma showed positive 
Bcl-2 expression (Fig. 3), and Pammer et al. (12), who 
observed a focal expression in one and a negative ex-
pression in the other. The positive expression shows that 
tumor cells in the myoepithelioma retain the ability to 
form different stromal components as seen in pleomor-
phic adenoma.
Both the cases of canalicular adenoma showed negative 
expression for Bcl-2, as these can be considered to be 
terminal differentiated tumor cells. Medline search did 
not reveal any study on Bcl-2 expression in ‘canalicular 
adenoma’.
Soini et al. (13) compared Bcl-2 expression in pleomor-
phic adenomas and in malignant salivary gland tumors 
comprising of mainly ACC and MEC, found 100% posi-
tivity in pleomorphic adenoma and 64% positivity in 
malignant tumors. In contrast, our study showed a simi-
lar but somewhat higher expression in similar malig-
Fig. 3. Photomicrograph showing intense Bcl-2 expression in Myo-
epithelioma (250X).
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nant salivary gland tumors (72%) and lesser expression 
in pleomorphic adenoma. Thus the cell survival rate is 
generally higher in malignant neoplasms than benign 
neoplasms. These observed differences in benign and 
malignant salivary gland neoplasms are of narrow 
range, which lack statistical significance. The lack of 
expression in pleomorphic adenoma may be attributed 
to the great variability in degree of epithelial cell dif-
ferentiation. 
There was no statistical significance in the expression 
or in the intensity between benign and malignant sali-
vary gland tumors. Ductal cells and myoepithelial cells 
were positive in all types of ACC, myoepithelial cells 
in myoepithelioma and most of the epidermoid cells in 
MEC. The terminally differentiated tumor cells of MEC 
and ductal cells of canalicular adenoma like, the nor-
mal acinar cells and ductal cells of salivary glands were 
negative. Bcl-2 expression in pleomorphic adenoma is 
variable due to the degree of differentiation. 
Conclusion
Bcl-2 expression was seen in all benign salivary gland 
tumors except canalicular adenoma. The study appears 
to be the first one in canalicular adenoma. A higher de-
gree of Bcl-2 expression is seen in malignant salivary 
gland tumors (78%) than in benign tumors (57%). This 
variable expression may be suggestive of a different 
susceptibility rate of tumor cells to apoptosis or ‘pro-
grammed cell death’. 
It is well established fact that morphology or appear-
ance of cells remains the mainstay in diagnosis of sali-
vary gland tumors. But, the immunohistochemistry is a 
valuable adjuvant in the diagnosis of malignant tumors 
of salivary gland origin as these have a very diverse his-
tology. Studies of a larger sample with a wide variety 
of benign as well as malignant salivary gland tumors 
comprising of all subtypes or variants of tumors are re-
quired to understand the significance of Bcl-2 expres-
sion in the prognosis as well as clinical outcome for the 
future generations.
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